Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Therapy Name | Mirvetuximab Soravtansine + SL-172154 |
Synonyms | |
Therapy Description | |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
Mirvetuximab Soravtansine | Elahere | IMGN853|M9346A-sulfo-SPDB-DM4|mirvetuximab soravtansine-gynx | FOLR1-targeted Therapy 24 | Elahere (mirvetuximab soravtansine) is an antibody-drug conjugate comprised of an antibody directed against FOLR1 linked to the tubulin polymerization-inhibiting drug DM4, leading to cell death in Folr1-expressing tumors (PMID: 26136852, PMID: 25904506). Elahere (mirvetuximab soravtansine) is FDA approved for use in patients with FOLR1-positive, platinum-resistant epithelial ovarian, fallopian tube, or primary peritoneal cancer, who have received one to three prior systemic treatments (FDA.gov). |
SL-172154 | SL172154|SL 172154|CD172a-Fc-CD40L Chimeric Protein SL-172154 | SL-172154 is a fusion protein that is engineered to target CD47 on tumor cells and CD40 on antigen presenting cells (APCs), which inhibits CD47/SIRPa signaling and potentially results in increased anti-tumor immune response (NCI Drug Dictionary). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT05483933 | Phase I | Pegylated liposomal doxorubicin + SL-172154 Mirvetuximab Soravtansine + SL-172154 | Phase 1b Study of SL-172154 Administered With Combination Agent(s) in Subjects With Ovarian Cancers | Active, not recruiting | USA | GBR | ESP | CAN | 0 |